PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Prelude Therapeutics Incorporated PRLD (“Prelude”) on behalf of the company’s investors. Since April 2023, shares of Prelude’s common stock have declined in value from a trading price of over $6.00 per share to a current…Read More
SHAREHOLDER ALERT Kaskela Law LLC Announces Investigation of Prelude Therapeutics Incorporated NASDAQ PRLD and Encourages Investors to Contact the Firm Prelude Therapeutics NASDAQPRLD
